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Most current articleTreatments for Crohn’s disease (CD) have been linked to serious infections, malignancies, and
dermatologic complications.Wepooledandanalyzedclinical trials of certolizumabpegol, apegylated
humanized Fab’ fragment against tumor necrosis factor, to quantify safety events in patientswith CD.METHODS: We collected data from 5 placebo-controlled trials, 9 open-label studies, and 1 dose-regimen
study, conducted globally through April 2014. A total of 2570 patients with moderate to severe
CD were treated with certolizumab pegol, with 4378.1 patient-years of exposure. Data were
analyzed in 2 groups: patients fromplacebo-controlled (PC) trials treatedwith placebo (n[ 875)
or certolizumab pegol (n [ 919) for 6 to 38 weeks (the PC group) or all patients exposed to
certolizumab pegol (n[ 2570), for durations of 6 to 362weeks (the all-studies group). Incidence
rates (IRs; incidence/100 patient-years) of adverse events (AEs) were calculated from ﬁrst dose
through 70 days (approximately 5 half-lives) after the last dose.RESULTS: In thePC group, IRs for seriousAEswere similar amongpatients given certolizumabpegol (31.35/
100 patient-years) vs placebo (24.33/100 patient-years). IRs of serious infections or malig-
nancies were low among patients receiving short-term treatment with certolizumab pegol (8.49/
100 patient-years and 1.01/100 patient-years, respectively, in the PC group) and did not increase
with long-term treatment (6.47/100 patient-years and 0.80/100 patient-years, respectively, in
the all-studies group). IRs of psoriasis or psoriasiform dermatitis were low in the PC group (1.01/
100 patient-years and 0/100 patient-years, respectively); in the placebo group, these IRs were
0.38 per 100 patient-years and 0 per 100 patient-years, respectively. IRs of psoriasis or psor-
iasiformdermatitis did not increasewith long-term treatment (0.93/100 patient-years and 0.09/
100 patient-years, respectively, in the all-studies group).CONCLUSIONS: Based on an analysis of data pooled from 15 trials of patients with CD, the safety proﬁle for long-
term therapywith certolizumabpegol therapy is similar to that reported fromshort-termstudies.
Overall rates of AEs, serious infections, malignancies, and psoriasis did not increase with long-
term treatment, suggesting a favorable risk–beneﬁt ratio with long-term certolizumab pegol
therapy in CD. Clinicaltrials.gov identiﬁers: NCT00291668, NCT00152490, NCT00152425,
NCT00308581, NCT00349752, NCT00552058, NCT00329550, NCT00329420, NCT00160524,
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1754 Loftus et al Clinical Gastroenterology and Hepatology Vol. 14, No. 12Crohn’s disease (CD) is a chronic inﬂammatorydisease that requires long-term treatment with
immunosuppressive therapy such as anti-tumor necrosis
factor-a (anti-TNFa) agents. As a therapeutic class,
anti-TNFa antagonists have been associated with
adverse events (AEs) including serious infections,1,2
malignancies,3 dermatologic complications such as mela-
noma,4 nonmelanoma skin cancers,5 psoriasiform skin
lesions,6,7 demyelinating events, drug-induced lupus-
like reactions, and congestive heart failure.8,9 Opportu-
nistic infections can be serious, but the absolute
incidence is low.9 The potential risk for lymphoprolifer-
ative diseases with anti-TNFa agents is also of interest,10
but current data are confounded by the widespread
use of immunomodulators such as azathioprine and
6-mercaptopurine.4,11,12
Certolizumab pegol, a subcutaneously administered
recombinant, humanized, polyethylene glycol–conjugated,
antigen-binding fragment (Fab’) with speciﬁcity for
human TNFa, is approved for the treatment of moderate
to severe CD in multiple countries. The safety of certoli-
zumab pegol during the treatment of CD has been
evaluated in placebo-controlled (PC) studies and
open-label (OL) studies.13–15
The aim of this retrospective pooled data analysis
was to assess the safety of certolizumab pegol in patients
with CD using data from UCB Pharma-sponsored and
UCB Pharma-conducted clinical trials. These data
allowed us to determine the incidence rates (IRs) of
clinically important AEs, a standard method for
measuring safety across studies.Methods
Studies and Designs
Data from 15 phase 2 through 3b UCB-conducted
studies of moderate to severe CD patients were pooled:
5 randomized PC studies (duration, 6–38 wk), 9 OL
studies (duration, 16 wk to 7 y), and 1 randomized, dose-
regimen study of certolizumab pegol (duration, 54 wk)
(Supplementary Table 1).13–22 Fourteen studies were
completed; 1 OL study was ongoing at the time of these
analyses (data cut-off date, April 14, 2012).
For PC studies, an induction of 400 mg certolizumab
pegol or placebo subcutaneously at weeks 0, 2, and 4
was followed by certolizumab pegol or placebo mainte-
nance administered as 400 mg every 4 weeks. Five of
the OL studies followed induction regimens with certoli-
zumab pegol; in all OL studies, maintenance certolizumab
pegol was administered at 400 mg every 4 weeks,
with 2 studies administering certolizumab pegol 400 mg
every 2 weeks for certain patients (Supplementary
Table 1).16,17
Study data originated from multicenter, multinational
(38 countries) clinical trials for the certolizumab pegol
program in CD.Adverse Events
Treatment-emergent AEs were deﬁned as any unto-
ward medical event starting on or after the ﬁrst dose and
within 70 days or fewer (approximately 5 half-lives) after
the last dose. Treatment-emergent serious AEs (SAEs)
were those that led to death; were life-threatening;
required in-patient hospitalization or extension of hospi-
talization; resulted in persistent or signiﬁcant disability/
incapacity, congenital anomalies, or birth defects; or
required medical or surgical intervention to prevent the
other criteria from occurring. Serious infections were
those requiring parenteral antibiotics and/or included
SAE criteria. Malignancies were identiﬁed by standard
Medical Dictionary for Regulatory Activities (MedDRA)
query: “malignant tumors.” Dermatologic events were
mapped to a high-level term of skin and subcutaneous
tissue disorders. In studies before 2007, screening for
tuberculosis (TB)was conducted according to the national
guidelines of the recruiting center (the criteria for a
positive puriﬁed protein derivative [PPD] test varied
between 5 and 20 mm). In 2007, protocols were
amended mandating that patients be treated prophylacti-
cally for TB if PPD positivity of 5 mm or greater was
observed at baseline.23,24 Data were probed for TB events
using the standardMedDRAquery: “tuberculosis infections,”
“Mycobacterium test positive,” “Mycobacterium tubercu-
losis complex test positive,” and “tuberculin test positive.”
All AE data were mapped to MedDRA version 15.1, and
the coding of AEs across studies was reviewed for con-
sistency. Prior medications were coded using the World
Health Organization (WHO) drug dictionary, June 2012.Statistical Methods
Safety data were divided into 2 separate CD pop-
ulations: the PC group (patients treated with either pla-
cebo or certolizumab pegol, allowing between-treatment
comparisons); and the all-studies group (all patients with
certolizumab pegol exposure, allowing safety assessment
of long-term certolizumab pegol exposure). All patients
who received at least 1 dose of study drug were
included. The data include 2 different placebo formula-
tions: saline and sorbitol. Certolizumab pegol data in the
PC group and all-studies group included patients who
received at least 1 dose of certolizumab pegol.
For IRs, the numerator was the total number of pa-
tients experiencing the AE; the denominator was the
summation of individual patient-years at risk up to the
ﬁrst occurrence of the AE plus the total patient-years at
risk for those patients not experiencing that AE, divided
by 100. IRs included a 95% conﬁdence interval (CI)
based on the chi-square distribution. For event rates, the
numerator was the total number of occurrences of an AE
(including repeat occurrences in individual patients)
divided by the total number of patient-years divided
by 100.
Table 1. Demographics and Disease Characteristics of 2570 Patients With Crohn’s Disease in the Integrated Safety Analysis
Placebo-controlled studies
All studies
Placebo (N ¼ 875) All CZP doses (N ¼ 919) All CZP doses (N ¼ 2570)
Age, median (range), y 36.0 (16–77) 35.0 (16–74) 35.0 (16–80)
Age category, n (%)
30 y 291 (33.3) 318 (34.6) 909 (35.4)
>30–60 to 64 y 562 (64.2) 584 (63.5) 1605 (62.5)
>64 y 22 (2.5) 17 (1.8) 56 (2.2)
Female, n (%) 476 (54.4) 483 (52.6) 1436 (55.9)
Race, n (%)
White 778 (88.9) 800 (87.1) 2339 (91.0)
Black or African American 22 (2.5) 20 (2.2) 47 (1.8)
Asian 44 (5.0) 77 (8.4) 117 (4.6)
American Indian or Alaskan Native 1 (0.1) 1 (0.1) 2 (0.1)
Hispanic or Latino 6 (0.7) 3 (0.3) 14 (0.5)
Mixed race 1 (0.1) 4 (0.4) 5 (0.2)
Other 23 (2.6) 14 (1.5) 46 (1.8)
BMI, mean (SD) 24.1 (5.4) 24.1 (5.7) 24.0 (5.5)
CDAI, mean (SD) 276.9 (84.2) 279.6 (84.4) 289.6 (76.9)
Duration of CD, mean (SD), y 7.6 (8.0) 7.9 (7.8) 8.6 (8.1)
Location of CD, n (%)
L1: terminal ileum 226 (25.8) 242 (26.3) 564 (21.9)
L2: colon 222 (25.4) 236 (25.7) 642 (25.0)
L3: ileocolon 379 (43.3) 396 (43.1) 1207 (47.0)
L4: upper GIa 48 (5.5) 45 (4.9) 156 (6.1)
Behavior of CD, n (%)
B1: inﬂammatory 614 (70.2) 631 (68.7) 1739 (67.7)
B2: stricturing 111 (12.7) 136 (14.8) 380 (14.8)
B3: penetrating 150 (17.1) 152 (16.5) 450 (17.5)
Resections performed, n (%) 273 (31.2) 294 (32.0) 880 (34.2)
Number of resections, n (%)
1 189 (21.6) 209 (22.7) 552 (21.5)
2 55 (6.3) 54 (5.9) 202 (7.9)
3 19 (2.2) 17 (1.8) 75 (2.9)
>3 10 (1.1) 12 (1.3) 49 (1.9)
Immunomodulator use,b n (%) 117 (13.4) 104 (11.3) 322 (12.5)
Corticosteroid use,b n (%) 226 (25.8) 228 (24.8) 636 (24.7)
Geographic region, n (%)
North America 278 (31.8) 284 (30.9) 778 (30.3)
Western Europe 120 (13.7) 121 (13.2) 731 (28.4)
Central Europe 213 (24.3) 203 (22.1) 423 (16.5)
Eastern Europe 88 (10.1) 99 (10.8) 201 (7.8)
ROW 176 (20.1) 212 (23.1) 437 (17.0)
Past medical history and concomitant diseases,c n (%)
Infections and infestations 202 (23.1) 237 (25.8) 742 (28.9)
Abdominal and gastrointestinal infections 56 (6.4) 61 (6.6) 234 (9.1)
Upper respiratory tract infections 44 (5.0) 53 (5.8) 150 (5.8)
Urinary tract infections 38 (4.3) 40 (4.4) 112 (4.4)
TB infections 1 (0.1) 1 (0.1) 2 (0.1)
Latent TB 0 (0.0) 1 (0.1) 1 (0.0)
TB 1 (0.1) 0 (0.0) 1 (0.0)
Neoplasmsd 54 (6.2) 45 (4.9) 149 (5.8)
Skin neoplasmse 7 (0.8) 4 (0.4) 12 (0.5)
Basal cell carcinoma 5 (0.6) 4 (0.4) 11 (0.4)
Keratoacanthoma 1 (0.1) 0 (0.0) 1 (0.0)
Skin cancer 1 (0.1) 0 (0.0) 0 (0.0)
BMI, body mass index; CDAI, Crohn’s Disease Activity Index; CZP, certolizumab pegol; GI, gastrointestinal; ROW, rest of the world (including Australia, Brazil,
Hong Kong, Japan, New Zealand, Russian Federation, Singapore, and South Africa).
aIf L4 was recorded then L1, L2, or L3 also must have been recorded.
bAt baseline of each study.
cAt the screening visit.
dBenign, malignant, and unspeciﬁed (including cysts and polyps).
eMalignant and unspeciﬁed (excluding melanoma).
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by dividing the number of observed treatment-emergent
deaths in the certolizumab pegol–exposed patients by
the number of expected deaths, calculated using 3
reference populations (the 2011 WHO general popula-
tion25 in countries where clinical studies contributed to
the certolizumab pegol pooled data and 2 CD populations
from the literature26,27).
All analyses were performed using SAS software
version 9.3 (SAS Institute, Inc, Cary, NC). All authors had
access to the study data, and reviewed and approved this
manuscript for publication.Results
Demographics and Disease Characteristics
Demographic and disease characteristics were
balanced across the PC group (placebo and certolizumab
pegol) and the all-studies group (Table 1). The mean
duration of CD ranged from 7.6 to 8.6 years. Prior re-
sections had been performed on nearly one third of pa-
tients at baseline.Exposure and Overall Safety
A total of 2570 patients were treated with certolizu-
mab pegol, with 4378.1 patient-years of exposure
(Supplementary Table 2). The median duration of cer-
tolizumab pegol treatment in the all-studies group was
254.0 days; 148 patients (5.8%) were treated with cer-
tolizumab pegol for more than 7 years.
In the PC group, IRs for any AEs were similar between
placebo- and certolizumab pegol–treated patients, and
did not increase with longer-term certolizumab pegol
exposure (Figure 1). The IR was nominally higher for
SAEs in the certolizumab pegol vs placebo group (95% CIfor each IR overlapped), and did not increase with longer
certolizumab pegol exposure (Table 2).
Mortality
In the PC group, no deaths were reported in the
certolizumab pegol group; 1 death occurred in the pla-
cebo group. Ten deaths occurred in the all-studies group
(Table 2 and Supplementary Table 3). One death in the
all-studies group occurred during an open-label exten-
sion study16 as a result of an AE during certolizumab
pegol treatment in the initial PC study.28
The SMR for the all-studies group, compared with the
2011 WHO general population, was 0.6 (95% CI,
0.3–1.2). The SMRs using the US26 and European Union27
CD cohorts as the reference populations were 0.2 (95%
CI, 0.1–0.4) and 0.2 (95% CI, 0.1–0.4), respectively.
Infections and Serious Infections
In the PC group, there was an increased risk for
infection with certolizumab pegol vs placebo (Table 2
and Figure 1). The IR for serious infectious complica-
tions was higher with certolizumab pegol than placebo
exposure in the PC studies (risk ratio, 1.57), and
remained steady with long-term certolizumab pegol
treatment. The most common serious infection in certo-
lizumab pegol–treated patients was pneumonia.
In the PC group, serious infections were more com-
mon in patients treated with certolizumab pegol than
placebo in all regions except Western Europe; the lowest
rate occurred in placebo-treated patients in Eastern
Europe (0.0%), whereas the highest rates were in cer-
tolizumab pegol–treated patients in the rest of the world
(ROW) (including Asia-Paciﬁc and South America, 4.2%).
Among patients in the all-studies group, the highest rate
of serious infections occurred in the ROW (13.7%), and
the lowest rate occurred in Eastern Europe (8.5%).Figure 1. Incidence rates
of AEs, serious AEs, in-
fections, and serious in-
fections (new cases per
100 patient-years).
Table 2. Summary of Treatment-Emergent AEs, Serious AEs, Serious Infections, and AEs Leading to Death Among
2570 Patients With Crohn’s Disease in the Integrated Safety Analysis
Placebo-controlled studies All studies
Placebo (N ¼ 875)
Total exposure: 261.7
patient-years
All CZP doses (N ¼ 919)
Total exposure: 298.7
patient-years
IR ratio
(CZP/placebo)
All CZP doses (N ¼ 2570)
Total exposure: 4378.1
patient-years
n (%) IRa ERa n (%) IRa ERa n (%) IRa ERa
Any AEs 610 (69.7) 560.88 881.08 647 (70.4) 514.28 899.92 0.92 2285 (88.9) 305.26 529.06
Serious AEs 61 (7.0) 24.33 37.06 88 (9.6) 31.35 44.53 1.29 854 (33.2) 24.19 36.04
AEs leading to
withdrawal
93 (10.6) 37.03 N/A 81 (8.8) 28.14 N/A 0.76 757 (29.5) 18.07 N/A
AEs related to
study drug
257 (29.4) 133.93 N/A 276 (30.0) 123.33 N/A 0.92 1309 (50.9) 50.53 N/A
AEs leading to
death
1 (0.1) 0.38 N/A 0b 0 N/A — 10 (0.4) 0.23 N/A
Any infection 248 (28.3) 122.10 138.31 326 (35.5) 151.45 171.08 1.24 1494 (58.1) 80.87 115.96
Any serious
infection
14 (1.6) 5.42 6.11 25 (2.7) 8.49 10.71 1 .57 268 (10.4) 6.47 7.65
Any infection
leading to
withdrawal
14 (1.6) 5.39 N/A 16 (1.7) 5.40 N/A 1.00 127 (4.9) 2.91 N/A
TB infections 0 0 0 1 (0.1) 0.34 0.33 — 10 (0.4) 0.23 0.23
Disseminated TB 0 0 0 0 0 0 — 2 (0.1) 0.05 0.05
Pulmonary TB 0 0 0 0 0 0 — 5 (0.2) 0.11 0.11
TB 0 0 0 1 (0.1) 0.34 0.33 — 3 (0.1)c 0.07 0.07
CZP, certolizumab pegol; ER, event rate (expressed as new events/100 patient-years); IR, incidence rate (expressed as new cases/100 patient-years); N/A, not
analyzed.
aIncidence or events/100 patient-years.
bOne AE was recorded during a PC study16 that resulted in death during the OLE,28 thus it is recorded among the all-studies group.
cOne case of disseminated TB was coded incorrectly as TB in the original study analysis.15
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ated with the development of serious infections during
treatment, the data were stratiﬁed by common baseline
demographic and clinical variables. Higher IRs for
serious infections were observed for certolizumab pegol
vs placebo exposure for most covariates analyzed;
exceptions were age older than 64 years, body mass
index less than 20 or 30 or greater, and Western Euro-
pean region (Table 3).
When data were stratiﬁed by corticosteroid use,
serious infections occurred at the highest frequency in
patients in the PC group treated with certolizumab pegol
and with corticosteroids (7 [3.1%]; IR, 10.35 [95% CI,
4.16–21.32]/100 patient-years), followed by certolizu-
mab pegol without corticosteroids (18 [2.6%]; IR, 7.93
[95% CI, 4.70–12.54]/100 patient-years), placebo with
corticosteroids (4 [1.8%]; IR, 6.60 [95% CI, 1.80–16.89]/
100 patient-years), and placebo without corticosteroids
(10 [1.5%]; IR, 5.05 [95% CI, 2.42–9.29]/100 patient-
years). In the all-studies group, serious infections
occurred more frequently in patients treated with cer-
tolizumab pegol and with corticosteroids (92 [14.5%];
IR, 7.73 [95% CI, 6.23–9.48]/100 patient-years) than in
patients treated with certolizumab pegol without corti-
costeroids (176 [9.1%]; IR, 5.96 [95% CI, 5.12–6.91]/100
patient-years).TB was reported in 10 certolizumab pegol–treated
patients and no placebo-treated patients (Table 2). The
risk of TB in the PC certolizumab pegol group did not
increase with long-term certolizumab pegol treatment.
One patient (age, 47 y at screening; white; female; from
South Africa) experienced disseminated TB after 2.6
years of continuous treatment with certolizumab pegol
that led to death; the case was reported as related to the
study drug by the investigator. No cases of TB were
reported in North America or Central Europe. There was
1 case and 1 positive PPD test in Western Europe; the
patient with the positive PPD test withdrew immediately
and no additional information was available. Eastern
Europe reported 1 case, and 7 cases were reported in
ROW locations.
Malignancies and Nonmelanoma Skin Cancers
The IR of malignancies was similar between certoli-
zumab pegol and placebo and did not increase with long-
term exposure, excluding nonmelanoma skin cancer
(NMSC) (Table 4). In the all-studies group treated with
certolizumab pegol, NMSC occurred in 13 patients
(0.5%); in this group, 1 patient with squamous cell
carcinoma (IR, 0.13; 95% CI, 0.00–0.74) and 2 patients
with basal cell carcinoma (IR, 0.27; 95% CI, 0.03–0.97)
Table 3. Summary of IRs of Serious Infectious Events Stratiﬁed by Baseline Demographic and Clinical Factors Among
2570 Patients With Crohn’s Disease in the Integrated Safety Analysis
Baseline characteristic
Placebo-controlled studies All studies
Placebo (N ¼ 875) CZP all doses (N ¼ 919) CZP all doses (N ¼ 2570)
n (%) IRa 95% CI n (%) IRa 95% CI n (%) IRa 95% CI
Overall 14 (1.6) 5.42 2.96–9.09 25 (2.7) 8.49 5.49–12.53 268 (10.4) 6.47 5.72–7.30
Age, y
30 6 (2.1) 7.34 2.69–15.98 11 (3.5) 11.19 5.59–20.03 107 (11.8) 8.32 6.82–10.06
>30 to 64 8 (1.4) 4.67 2.02–9.21 14 (2.4) 7.39 4.04–12.40 153 (9.5) 5.50 4.66–6.44
>64 0 0 N/A 0 0 N/A 8 (14.3) 10.90 4.71–21.49
Sex
Male 7 (1.8) 5.80 2.33–11.94 13 (3.0) 9.56 5.09–16.35 113 (10.0) 5.74 4.73–6.90
Female 7 (1.5) 5.08 2.04–10.47 12 (2.5) 7.57 3.91–13.21 155 (10.8) 7.14 6.06–8.36
BMI, kg/m2
<20 6 (3.1) 11.39 4.18–24.79 7 (3.1) 11.16 4.49–23.00 71 (11.6) 8.10 6.33–10.22
20 to <30 7 (1.2) 4.10 1.65–8.44 18 (3.1) 9.36 5.55–14.79 164 (10.0) 6.02 5.13–7.01
30 to <35 0 0 N/A 0 0 N/A 26 (12.6) 7.74 5.06–11.34
35 1 (2.6) 7.97 0.20–44.39 0 0 N/A 6 (5.2) 2.96 1.09–6.45
Corticosteroid use
Yes 4 (1.8) 6.60 1.80–16.89 7 (3.1) 10.35 4.16–21.32 92 (14.5) 7.73 6.23–9.48
No 10 (1.5) 5.05 2.42–9.29 18 (2.6) 7.93 4.70–12.54 176 (9.1) 5.96 5.12–6.91
Immunomodulator use
Yes 2 (1.7) 7.02 0.85–25.38 4 (3.8) 11.94 3.25–30.57 57 (17.7) 8.38 6.35–10.86
No 12 (1.6) 5.22 2.70–9.11 21 (2.6) 8.04 4.98–12.30 211 (9.4) 6.10 5.30–6.98
Prior anti-TNF use
Yes 2 (1.3) 4.23 0.51–15.27 6 (3.3) 9.91 3.64–21.57 105 (10.9) 9.86 8.06–11.93
No 12 (1.7) 5.68 2.94–9.92 19 (2.6) 8.12 4.89–12.68 163 (10.1) 5.30 4.52–6.18
Prior use of other medications of interest
Yes 9 (1.7) 5.37 2.45–10.19 17 (3.0) 9.10 5.30–14.57 144 (10.4) 5.40 4.55–6.36
No 5 (1.5) 5.50 1.79–12.84 8 (2.3) 7.43 3.21–14.64 124 (10.4) 8.41 7.00–10.03
Geographic region
North America 4 (1.4) 4.88 1.33–12.50 6 (2.1) 6.34 2.33–13.80 69 (8.9) 6.18 4.81–7.82
Western Europe 5 (4.2) 14.42 4.68–33.65 3 (2.5) 7.86 1.62–22.98 75 (10.3) 9.62 7.57–12.06
Central Europe 1 (0.5) 1.34 0.03–7.47 5 (2.5) 6.67 2.17–15.57 47 (11.1) 3.92 2.88–5.22
Eastern Europe 0 0 N/A 2 (2.0) 5.45 0.66–19.68 17 (8.5) 3.76 2.19–6.03
ROW 4 (2.3) 9.78 2.67–25.05 9 (4.2) 17.97 8.22–34.11 60 (13.7) 10.08 7.69–12.97
Smoking status
Never 4 (1.1) 4.04 1.10–10.34 11 (3.1) 9.84 4.91–17.61 100 (9.8) 5.55 4.51–6.75
Former 1 (0.7) 2.41 0.06–13.42 3 (1.8) 5.50 1.14–16.08 45 (9.7) 5.41 3.95–7.24
Current 5 (2.1) 6.94 2.25–16.20 7 (3.1) 9.40 3.78–19.36 89 (12.5) 7.71 6.19–9.49
Missing 4 (2.9) 8.70 2.37–22.29 4 (2.3) 7.43 2.02–19.03 34 (9.0) 9.68 6.70–13.52
BMI, body mass index; CZP, certolizumab pegol; N/A, not analyzed.
aIncidence/100 patient-years.
Table 4.Malignancies of Interest Among 2570 Patients With Crohn’s Disease in the Integrated Safety Analysis
Placebo-controlled studies All studies
Placebo (N ¼ 875) CZP all doses (N ¼ 919) CZP all doses (N ¼ 2570)
n (%) IRa (95% CI) n (%) IRa (95% CI) n (%) IRa (95% CI)
Any malignancy 3 (0.3) 1.2 (0.2–3.4) 3 (0.3) 1.0 (0.2–2.9) 35 (1.4) 0.8 (0.6–1.1)
Nonmelanoma skin cancers 0 0 1 (0.1) 0.3 (0.0–1.9) 13 (0.5) 0.3 (0.2–0.5)
Skin melanoma 0 0 0 0 4 (0.2) 0.1 (0.0–0.2)
Hodgkin’s lymphoma 1 (0.1) 0.4 (0.0–2.1) 0 0 0 0
Non-Hodgkin’s lymphoma 0 0 0 0 1 (0.0) 0.0 (0.0–0.1)
HSTCL 0 0 0 0 0 0
CZP, certolizumab pegol; HSTCL, hepatosplenic T-cell lymphoma; IR, incidence rate (expressed as new cases/100 patient-years).
aEvents/100 patient-years.
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Melanoma occurred in 4 patients (0.2%). Hodgkin’s
lymphoma was reported in 1 patient in the placebo
group; no cases were reported in certolizumab
pegol–treated patients in the PC group. Non-Hodgkin’s
lymphoma occurred in 1 certolizumab pegol–treated
patient in the OL studies (IR, 0.02; 95% CI, 0.00–0.13).
Dermatologic Complications
Psoriatic conditions were the most frequently re-
ported skin complications (Table 5). However, in the PC
group, the rates of overall psoriatic events were low in
both placebo- and certolizumab pegol–treated patients;
the risk was stable with longer certolizumab pegol
exposure. During the PC group, the only events were
classiﬁed as psoriasis, whereas in the all-studies group,
cases of dermatitis psoriasiform, guttate psoriasis, and
pustular psoriasis were recorded (4 patients with each
condition). There were no cases of drug-induced lupus-
like syndrome, Stevens–Johnson’s reaction, or toxic
epidermal necrosis.
Other Events
Early hypersensitivity to subcutaneous certolizumab
pegol injections was explored with a broad search of all
AEs that occurred within 2 hours of treatment. Because
of the age or conditions of some pooled studies, it was
not possible to conﬁrm the hypersensitivity events.
The overall IR of AEs that may have been earlyTable 5. Summary of Nonmalignant Dermatologic Complication
Safety Analysis
High-level term
Preferred term
Placebo-cont
Placebo
(N ¼ 875)
n (%) IRa
Any skin event 87 (9.9) 36.50
Serious skin events 1 (0.1) 0.38
Psoriatic conditions 1 (0.1) 0.38
Dermatitis psoriasiform 0 0
Guttate psoriasis 0 0
Psoriasis 1 (0.1) 0.38
Pustular psoriasis 0 0
Skin vasculitides 0 0
Leukocytoclastic vasculitis 0 0
Bullous conditions 2 (0.2) 0.77
Erythema multiforme 0 0
Alopecias 3 (0.3) 1.15
Alopecia (not speciﬁed) 3 (0.3) 1.15
Alopecia areata 0 0
Alopecia totalis 0 0
Madarosis 0 0
CZP, certolizumab pegol; IR, incidence rate.
aEvents/100 patient-years.hypersensitivity reactions was 5.10 per 100 patient-
years among those treated with certolizumab pegol in
the PC group and 5.44 per 100 patient-years for placebo,
and did not increase with the all-studies group (3.27/
100 patient-years). The most commonly reported events
were rash (1.4%), pruritus (0.9%), cough (0.7%), and
erythema (0.6%).
There was 1 event of demyelinating polyneuropathy
in the all-studies group (IR, 0.02/100 patient-years),
which was reported as related to the study drug. There
were no cases of Guillain–Barré syndrome, aseptic
meningoencephalitis, leukoencephalopathy, transverse
myelitis, progressive multifocal leukoencephalopathy, or
posterior reversible encephalopathy syndrome. There
were no cases of lupus-like syndrome in any treatment
group, and only 1 case of antinuclear antibody increase
occurred in the all- studies group. There were no data to
suggest an effect of certolizumab pegol on heart failure in
patients with CD.
Discussion
Immunomodulator treatments for CD may lead to an
impaired immune response and AEs.10,29 In these pooled
analyses of 15 UCB-conducted clinical studies, the safety
proﬁle of certolizumab pegol was consistent with short-
term studies15,30,31 and with the few data available for
long-term exposure.16,32,33 No major differences in most
AE IRs were noted between certolizumab pegol and
placebo in the PC group. The overall rates of AEs or
SAEs with certolizumab pegol did not increase froms Among 2570 Patients With Crohn’s Disease in the Pooled
rolled studies All studies
CZP all doses
(N ¼ 919)
CZP all doses
(N ¼ 2570)
n (%) IRa n (%) IRa
107 (11.6) 39.07 724 (28.2) 22.30
0 0 11 (0.4) 0.25
3 (0.3) 1.01 46 (1.8) 1.07
0 0 4 (0.2) 0.09
0 0 1 (0.0) 0.02
3 (0.3) 1.01 40 (1.6) 0.93
0 0 2 (0.1) 0.05
0 0 1 (0.0) 0.02
0 0 1 (0.0) 0.02
1 (0.1) 0.34 6 (0.2) 0.14
0 0 1 (0.0) 0.02
4 (0.4) 1.34 46 (1.8) 1.06
3 (0.3) 1.01 40 (1.6) 0.92
1 (0.1) 0.34 5 (0.2) 0.11
0 0 1 (0.0) 0.02
0 0 1 (0.0) 0.02
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that certolizumab pegol may not have a cumulative dose
or duration effect, which supported previous ﬁndings.16
Patients with CD have higher rates of death than the
overall population, with an SMR for the overall CD pop-
ulation of 1.2 to 1.9 times higher.26,27 Treatment of CD
with adalimumab reduced the SMR to 0.45 (95% CI,
0.15–1.06) relative to a reference population with CD.32
Treatment with certolizumab pegol in these analyses
showed that the all-studies group had similar SMRs to
the overall population in the countries where certolizu-
mab pegol was tested,25 and reduced SMRs relative to
the overall populations of patients with CD in the United
States and the European Union (IR, 0.23).26,27
Patients receiving anti-TNFa therapies may be at
increased risk of infections32,34–36 as a result of cortico-
steroid use, an inadequate immune response, comor-
bidities, or a combination of other factors.29,32 Our
analyses found an increase in the rate of serious in-
fections with certolizumab pegol compared with placebo
(risk ratio, 1.57), but no increased risk with a longer
duration of exposure. Analyses from the Crohn’s Ther-
apy, Resource, Evaluation and Assessment Tool (TREAT)
registry for treatment of CD found an increased risk of
serious infections with inﬂiximab relative to other
treatments (unadjusted relative risk ratio, 2.04).36
These data suggest that long-term certolizumab pegol
treatment is not associated with an additional increased
risk of TB, and the IR was consistent with other studies
of anti-TNFa therapies.32 All conﬁrmed TB cases were in
countries outside North America, Western Europe, and
Central Europe. These data support the need for
screening and surveillance of TB during treatment,
especially in high-risk regions.
Our analyses suggests that certolizumab pegol treat-
ment does not increase the risk of malignancies compared
with placebo; therewas no evidence of an increased risk of
malignancies with longer exposure to certolizumab pegol,
supporting previous ﬁndings in which the risk with anti-
TNFa agents was similar to the general popula-
tion.12,32,37,38 These data add to previous studies that
showed little or no increase in the risk of lymphoproli-
ferative diseases or melanoma in patients treated with
anti-TNFa.4,10,11,39 Non-Hodgkin’s lymphoma occurred at
a lower IR (0.02/100 patient-years) than previous meta-
analyses for anti-TNFa agents, which reported 6.1 per
10,000 patient-years, close to estimates for the general
population at 1.9 per 10,000 person-years.10 Previous
meta-analyses found that the odds ratio of lymphomawith
biologic treatment was not signiﬁcantly different from
control treatments.9,10 These analyses showed a very low
incidence of NMSC (IR, 0.3/100 patient-years), similar to
previous studies of adalimumab that showed the risk of
NMSC was similar to the overall population.38 Anti-TNFs
in combination with immunosuppressants have been
associatedwithNMSC40; in this study, the IR forNMSCwas
less than 0.3 per 100 patient-years for patients treated
with certolizumab pegol and immunosuppressants.Data herein suggest that certolizumab pegol may not
be associated with a high rate of dermatologic compli-
cations. Psoriatic lesions, the most common dermatologic
event, typically occur in less than 5% of patients treated
with anti-TNF agents and the primary risk factor is
smoking.41
Recent data have suggested that, because of the lack
of Fc region, certolizumab pegol may be less likely to
induce antinuclear antibodies or lupus-like reactions
than inﬂiximab or adalimumab.42 In these studies with
up to 7.5 years of certolizumab pegol treatment, no cases
of lupus-like syndrome were reported, and only 1 case of
increased antinuclear antibodies was reported in the all-
studies group.
In summary, in the all-studies certolizumab pegol
group (including patients treated for up to 7.5 years) the
IRs for AEs were stable over time, suggesting that
the risk of AEs does not increase with longer exposure.
The extended treatment period with certolizumab pegol
should have provided sufﬁcient time to record all clini-
cally relevant AEs. The certolizumab pegol safety data
described provides critical validation of the safety proﬁle
of certolizumab pegol for the treatment of CD.
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